Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus in Saudi Arabia: A Post Authorization Safety Study
Crossref DOI link: https://doi.org/10.1007/s13300-021-01092-0
Published Online: 2021-06-12
Published Print: 2021-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Alguwaihes, Abdullah M.
Funding for this research was provided by:
AstraZeneca
Text and Data Mining valid from 2021-06-12
Version of Record valid from 2021-06-12
Article History
Received: 18 April 2021
Accepted: 28 May 2021
First Online: 12 June 2021